Table 1.
Description of the characteristics of the study population by COVID-19 vaccine uptake.
| Characteristics | Total | No vaccine | 2 or Less vaccines | 3 or More vaccinesA |
|---|---|---|---|---|
| N = 1885 | N = 179 (10%) | N = 697 (37%) | N = 1009 (54%) | |
| Age (median, IQR) | 50.1 (41.5–58.3) | 47.2 (40.5–57.7) | 46.0 (38.6–52.5) | 54.0 (43.9–61.4) |
| < 40 years | 406 (22%) | 42 (23%) | 204 (29%) | 160 (16%) |
| 40–50 years | 531 (28%) | 56 (31%) | 254 (36%) | 221 (22%) |
| 50–60 years | 564 (30%) | 51 (28%) | 180 (26%) | 333 (33%) |
| > 60 years | 384 (20%) | 30 (17%) | 59 (8%) | 295 (29%) |
| Birth sex | ||||
| Male | 1356 (72%) | 120 (67%) | 418 (60%) | 818 (81%) |
| Female | 529 (28%) | 59 (33%) | 279 (40%) | 191 (19%) |
| Ethnicity/race | ||||
| Non-Hispanic white | 893 (47%) | 95 (53%) | 206 (30%) | 592 (59%) |
| Non-Hispanic black | 542 (29%) | 48 (27%) | 325 (47%) | 169 (17%) |
| First nations | 117 (6%) | 12 (7%) | 57 (8%) | 48 (5%) |
| Other/unknownB | 333 (18%) | 24 (13%) | 109 (16%) | 200 (20%) |
| HIV acquisition risk category | ||||
| MSM/Bisexual | 782 (41%) | 47 (26%) | 166 (24%) | 569 (56%) |
| Heterosexual | 835 (44%) | 94 (53%) | 419 (60%) | 322 (32%) |
| PWID | 148 (8%) | 23 (13%) | 56 (8%) | 69 (7%) |
| Other/unknownC | 120 (6%) | 15 (8%) | 56 (8%) | 49 (5%) |
| Nadir CD4 category | ||||
| > 500 cells/mm3 | 175 (9%) | 23 (13%) | 71 (10%) | 81 (8%) |
| 200–500 cells/mm3 | 857 (45%) | 79 (44%) | 328 (47%) | 450 (45%) |
| < 200 cells/mm3 | 849 (45%) | 75 (42%) | 297 (43%) | 477 (47%) |
| Missing | 4 (0%) | 2 (1%) | 1 (0%) | 1 (0%) |
| CD4 category | ||||
| > 500 cells/mm3 | 880 (47%) | 65 (36%) | 309 (44%) | 506 (50%) |
| 200–500 cells/mm3 | 682 (36%) | 53 (30%) | 252 (36%) | 377 (37%) |
| < 200 cells/mm3 | 115 (6%) | 12 (7%) | 59 (8%) | 44 (4%) |
| Not measured over study period | 208 (11%) | 49 (27%) | 77 (11%) | 82 (8%) |
| Viral load category | ||||
| < 200 copies/mL | 1635 (87%) | 111 (62%) | 580 (83%) | 944 (94%) |
| ≥ 200 copies/mL | 137 (7%) | 30 (17%) | 72 (10%) | 35 (3%) |
| Not measured over study period | 113 (6%) | 38 (21%) | 45 (6%) | 30 (3%) |
| Ever incarcerated | 110 (6%) | 15 (8%) | 52 (7%) | 43 (4%) |
| Initial vaccine type | ||||
| Moderna | 409 (22%) | 0 (0%) | 195 (28%) | 214 (21%) |
| Pfizer-BioNTech | 1297 (69%) | 0 (0%) | 502 (72%) | 795 (79%) |
| Education level | ||||
| < 12 years | 352 (19%) | 44 (25%) | 172 (25%) | 136 (13%) |
| 12 years | 426 (23%) | 47 (26%) | 169 (24%) | 210 (21%) |
| > 12 years | 906 (48%) | 55 (31%) | 264 (38%) | 587 (58%) |
| Missing/unknown | 201 (11%) | 33 (18%) | 92 (13%) | 76 (8%) |
| LocationD | ||||
| Metropolitan | 1495 (79%) | 126 (70%) | 566 (81%) | 803 (80%) |
| Non-Metropolitan | 374 (20%) | 50 (28%) | 126 (18%) | 198 (20%) |
| Missing | 16 (1%) | 3 (2%) | 5 (1%) | 8 (1%) |
| Housing status | ||||
| Unstable housing/homeless | 182 (10%) | 24 (13%) | 74 (11%) | 84 (8%) |
| Body mass index | ||||
| < 25 kg/m2 | 544 (29%) | 57 (32%) | 190 (27%) | 297 (29%) |
| ≥ 25 kg/m2 | 1034 (55%) | 85 (47%) | 354 (51%) | 595 (59%) |
| Missing | 307 (16%) | 37 (21%) | 153 (22%) | 117 (12%) |
| History of substance use | 261 (14%) | 36 (20%) | 93 (13%) | 132 (13%) |
| Comorbidities | ||||
| Malignancy | 155 (8%) | 12 (7%) | 35 (5%) | 108 (11%) |
| Hypertension | 240 (13%) | 17 (9%) | 64 (9%) | 159 (16%) |
| Renal disease | 61 (3%) | 4 (2%) | 15 (2%) | 42 (4%) |
| Cardiovascular disease | 64 (3%) | 4 (2%) | 12 (2%) | 48 (5%) |
| Asthma or COPD | 201 (11%) | 19 (11%) | 55 (8%) | 127 (13%) |
| Diabetes mellitus | 163 (9%) | 7 (4%) | 54 (8%) | 102 (10%) |
IQR—Interquartile range, MSM—men who have sex with men, PWID—people who use injection drugs, COPD—chronic obstructive pulmonary disease.
ABooster dose defined as receiving 3 or more COVID-19 vaccinations.
BOther Ethnicity/Race includes Hispanic, East-Asian, West-Asian, Indo-Asian, or other.
COther HIV risk acquisition group includes blood transfusion, hemophilia or perinatal transmission.
DLocation defined as most recent place of residence, metropolitan and non-metropolitan (city of > 1 million people) or rural (< 1 million people).